Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Imine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120758580A reveals enzymatic route for (S)-chiral amines. High ee value, mild conditions. Reliable supplier for pharma intermediates.
Patent CN114539327B reveals stable P,N,N-ligand for propargyl conversion. Offers supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN112852771A details enzymatic synthesis of chiral amino alcohols using imine reductase, offering high stereoselectivity and mild conditions for pharmaceutical manufacturing.
Patent CN107304176A details a mild chiral synthesis route for alpha-fluoro beta-amino acids, offering high optical purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN110128357B reveals a mild Cs2CO3-catalyzed route for pyrazine derivatives, offering high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN102627590A details a mild route to chiral alpha-tribromomethyl amines. Offers high optical purity and scalable conditions for API intermediates.
Patent CN114736882B reveals high-efficiency biocatalysis for antiviral intermediates. Offers supply chain stability and cost reduction in API manufacturing without heavy metals.
Patent CN114989058B reveals a metal-free catalytic route for high-purity chiral chlorosulfoximines, offering significant cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Patent CN114381441B reveals imine reductase catalysis for optical pure chiral amino alcohols. Offers mild conditions and high stereoselectivity for pharmaceutical supply chains.
Patent CN101801984A details novel chiral phosphoramides and N-phosphonimines. Discover stable alternatives to N-sulfinylimines for cost-effective asymmetric synthesis.
Patent CN102304007B reveals high-ee asymmetric hydrogenation using chiral Ru catalysts enabling cost reduction in pharmaceutical intermediate manufacturing with scalable processes.
Novel iron-catalyzed asymmetric hydrogenation technology using chiral quinoline imidazoline ligands. Reduces noble metal dependency for high-purity pharmaceutical intermediates.